Lifeboat Foundation

Northwestern Medicine investigators have developed a novel nanoparticle treatment for glioblastoma, according to a study published in Nature Communications.

Glioblastoma, the most common type of primary brain cancer, is one of the most complex, deadly and treatment-resistant cancers, according to the National Brain Tumor Society. The five-year survival rate for glioblastoma patients hovers near 7% and has remained unchanged for decades.

Previous Northwestern Medicine research has shown that glioblastoma tumors accumulate large numbers of immunosuppressive tumor-associated myeloid cells (TAMCs), which impairs the immune system’s ability to fight the tumor and reduces the effectiveness of radiation and chemotherapy.

Why does all of this matter? The unfortunate truth is that each of us will experience plenty of mental pain, misery, and frustration in our lifetimes. Mistaking the voice in our head for a thing and labeling it “me” brings us into conflict with the neuropsychological evidence that shows there is no such thing. This mistake — this illusory sense of self — is the primary cause of our mental suffering. When you can’t sleep at night, is it because you are worried about a stranger’s problems, or is it your problems that keep you up? For most of us, we worry about my work problems, my money problems, and my relationship problems. What would happen if we removed the “self” from these problems?

I am distinguishing mental suffering from physical pain. Pain occurs in the body and is a physical reaction—like when you stub your toe or break an arm. The suffering I speak of occurs in the mind only and describes things such as worry, anger, anxiety, regret, jealousy, shame, and a host of other negative mental states. I know it’s a big claim to say that all these kinds of suffering are the result of a fictitious sense of self. For now, the essence of this idea is captured brilliantly by Taoist philosopher and author Wei Wu Wei when he writes, “Why are you unhappy? Because 99.9 percent of everything you think, and of everything you do, is for yourself — and there isn’t one.”

Multiple sclerosis (MS) affects roughly 2.5 million people worldwide and is a neurological disease affecting the brain and spinal cord. More specifically, MS is when the immune system attacks the body’s protective layer around nerve fibers known as myelin sheaths. The breakdown of myelin sheath leads to a disconnect between your brain and body. The immune cells responsible for myelin sheath deterioration include CD4+ T cells, or effector cells, which are part of the body’s first line of defense. In MS, the effector cells do not recognize that the myelin sheath is a normal part of the body. Therefore, the effector cells become the dominant cell type, trying to kill and get rid of the myelin sheath. The immune response will generate inflammation which destroys the myelin sheath leading to a disruption of signals along the nerves from the brain to the body.

A group of researchers at Johns Hopkins University School of Medicine recently published a therapy that controls the symptoms of MS. The goal of the therapy was to stop effector cells from attacking the myelin sheath and to promote the production of T regulatory cells-or T regs-which have been demonstrated to reduce autoimmune effects.

Dr. Giorgio Raimondi, PhD, MSc, Jordan Green, and others used three therapeutic agents to control MS symptoms. Researchers used microparticles, which are small, bioengineered spheres to deliver the agents. The first agent is a combination of two proteins which include Interleukin-2 (IL2) and an antibody that promotes T reg production. IL2 stimulates T cell expansion, while the antibody blocks specific parts of IL2 to specifically expand T regs compared to effector cells. The second agent includes a molecule that presents a protein specific to myelin so that the immune response will generate T regs specifically designed to protect the myelin sheath. Finally, the third agent is rapamycin, which is an immunosuppressant drug designed to reduce effector T cells.

We’ve been waxing lyrical (and critical) about Apple’s Vision Pro here at TechCrunch this week – but, of course, there are other things happening in the world of wearable tech, as well. Sol Reader raised a $5 million seed round with a headset that doesn’t promise to do more. In fact, it is trying to do just the opposite: Focus your attention on just the book at hand. Or book on the face, as it were.

“I’m excited to see Apple’s demonstration of the future of general AR/VR for the masses. However, even if it’s eventually affordable and in a much smaller form factor, we’re still left with the haunting question: Do I really need more time with my smart devices,” said Ben Chelf, CEO at Sol. “At Sol, we’re less concerned with spatial computing or augmented and virtual realities and more interested in how our personal devices can encourage us to spend our time wisely. We are building the Sol Reader specifically for a single important use case — reading. And while Big Tech surely will improve specs and reduce cost over time, we can now provide a time-well-spent option at 10% of the cost of Apple’s Vision.”

The device is simple: It slips over your eyes like a pair of glasses and blocks all distractions while reading. Even as I’m typing that, I’m sensing some sadness: I have wanted this product to exist for many years – I was basically raised by books, and lost my ability to focus on reading over the past few years. Something broke in me during the pandemic – I was checking my phone every 10 seconds to see what Trump had done now and how close we were to a COVID-19-powered abyss. Suffice it to say, my mental health wasn’t at its finest – and I can’t praise the idea of Sol Reader enough. The idea of being able to set a timer and put a book on my face is extremely attractive to me.

Worth a listen to understand the current reality and the future potential:

Go to https://ground.news/sabine to stay fully informed on breaking news, compare coverage and avoid media bias. Subscribe using my link to get 30% off the Vantage plan for unlimited access.

Continue reading “Should we take evolution into our own hands and become transhuman?” »

A human brain-to-brain interaction experiment lets one man’s thoughts control another person’s movements.

Chemical signals from contracting muscles can influence the growth of brain networks, according to new research published in Neuroscience. The study highlights the importance of physical activity to mental health, and the findings could also help contribute to the development of more effective treatments for cognitive disorders such as Alzheimer’s disease.

Previous studies had shown that exercise has significant benefits for cognitive health, even when initiated at late stages in life. Exercise has been associated with long-term changes in the hippocampus, a brain region crucial for learning and memory, including increased neurogenesis, synaptogenesis, and enlarged volume.

However, the specific mechanisms through which exercise produces these changes in the hippocampus were not well understood. By uncovering these mechanisms, the authors behind the new study aim to develop exercise-based treatments for cognitive pathologies that affect the hippocampus, such as Alzheimer’s disease, stress, depression, anxiety, and normal aging.

Scientists at the University of Texas at Austin have created a “semantic brain decoder” to guess someone’s thoughts based on brain activity.

During tests, it captured the gist of what someone was thinking, rather than a literal translation. And if participants resisted, it produced gibberish.

The decoder, written about in the journal Nature Neuroscience in May, is novel, said Edmund Lalor, an associate professor of neuroscience at the University of Rochester. But its threat to privacy is minimal.

Researchers have found that well-managed weight through a healthy diet, including Mediterranean-type diets, can help reduce brain aging and improve brain health.